Abstract Background (Neo)adjuvant systemic treatments aim to improve overall survival by reducing recurrence risk; however, there can be challenges, such as reliance on surrogate endpoints, censoring, loss to follow-up, and impact on quality of life. We examine the design, reporting, and outcomes of US Food and Drug Ad...
C. M. Valiente, A. Mittal, Dong-Sheng Tu et al.· Journal of the National Canc...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.